Cyclacel Pharmaceuticals (CYCC) Institutional Ownership → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free CYCC Stock Alerts $2.29 -0.05 (-2.14%) (As of 05/17/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Cyclacel Pharmaceuticals (NASDAQ:CYCC)CurrentInstitutional OwnershipPercentage23.58%Number ofInstitutional Buyers(last 12 months)0Number ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$20.97K Get CYCC Insider Trade Alerts Want to know when executives and insiders are buying or selling Cyclacel Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CYCC Institutional Buying and Selling by Quarter Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. Cyclacel Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/10/2024 Acadian Asset Management LLC14,285$29K0.0%-41.0%1.084% 11/1/2022 Kestra Advisory Services LLC23,000$34K0.0%N/A0.183% 10/25/2022 Raymond James Financial Services Advisors Inc.20,806$30K0.0%-32.5%0.166% 10/18/2022 McIlrath & Eck LLC26,342$38K0.0%N/A0.210% 8/15/2022 Sio Capital Management LLC454,355$491K0.2%+7.5%4.546% 2/10/2022 Acadian Asset Management LLC23,242$89K0.0%N/A0.233% Get the Latest News and Ratings for CYCC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/16/2021 Two Sigma Advisers LP121,500$640K0.0%+929.7%1.316% 11/15/2021 Pura Vida Investments LLC105,141$554K0.0%-33.2%1.139% 11/15/2021 Tri Locum Partners LP522,943$2.76M1.1%+66.9%5.663% 11/12/2021 Affinity Asset Advisors LLC400,000$2.11M0.5%+5.3%4.332% 11/2/2021 Raymond James Financial Services Advisors Inc.10,006$53K0.0%-83.3%0.108% 10/15/2021NEXT Financial Group Inc14,752$77K0.0%+70.0%0.160% 8/18/2021 Ikarian Capital LLC100,000$593K0.0%-66.7%1.083% 8/17/2021 Boothbay Fund Management LLC10,545$62K0.0%-66.7%0.114% 8/17/2021 Citadel Advisors LLC250,797$1.49M0.0%-14.7%2.716% 8/16/2021 Tri Locum Partners LP313,331$1.86M0.6%+6.8%3.393% 8/16/2021 Schonfeld Strategic Advisors LLC102,525$607K0.0%-25.0%1.110% 8/16/2021 Maven Securities LTD234,500$1.43M0.1%-6.2%2.540% 8/13/2021 Northern Trust Corp14,957$89K0.0%N/A0.162% 8/13/2021 Geode Capital Management LLC50,860$301K0.0%+143.3%0.551% 8/13/2021 Vanguard Group Inc.327,658$1.94M0.0%+9.2%3.548% 7/31/2021NEXT Financial Group Inc8,680$51K0.0%N/A0.094% 5/19/2021Virtu Financial LLC13,108$93K0.0%+27.3%0.142% 5/19/2021 Squarepoint Ops LLC23,836$169K0.0%N/A0.258% 5/18/2021 Point72 Asset Management L.P.230,000$1.64M0.0%N/A2.491% 5/18/2021 Verition Fund Management LLC116,674$830K0.0%N/A1.264% 5/18/2021 Morgan Stanley100,000$711K0.0%-13.0%1.083% 5/18/2021 Citadel Advisors LLC293,867$2.09M0.0%N/A3.182% 5/18/2021 Silverarc Capital Management LLC250,000$1.78M1.0%N/A2.707% 5/17/2021 Schonfeld Strategic Advisors LLC136,725$972K0.0%N/A1.481% 5/17/2021 Sphera Funds Management LTD.508,322$3.61M0.3%N/A5.505% 5/17/2021 Ikarian Capital LLC300,000$2.13M0.1%-23.4%3.249% 5/12/2021 Geode Capital Management LLC20,904$148K0.0%N/A0.226% 5/12/2021 Pura Vida Investments LLC273,958$1.95M0.1%-42.3%2.967% 5/11/2021 Acadian Asset Management LLC34,057$242K0.0%N/A0.369% 4/12/2021 Valeo Financial Advisors LLC4,500$32K0.0%N/A0.063% 2/24/2021Virtu Financial LLC10,293$80K0.0%N/A0.212% 2/16/2021 Pura Vida Investments LLC475,000$3.71M0.1%N/A9.766% 2/16/2021 Acuta Capital Partners LLC150,000$1.17M0.3%N/A3.084% 2/12/2021 Raymond James Financial Services Advisors Inc.57,006$445K0.0%+24.6%1.172% Elon’s New Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake.2/12/2021 Ikarian Capital LLC391,450$3.06M0.1%N/A8.048% 11/4/2020 Raymond James Financial Services Advisors Inc.45,756$167K0.0%+48.8%0.941% 7/17/2020 Raymond James Financial Services Advisors Inc.30,756$143K0.0%-48.8%0.633% 7/16/2020 Wedbush Securities Inc.29,300$136K0.0%N/A0.603% (Data available from 1/1/2016 forward) CYCC Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CYCC shares? During the previous two years, the following institutional investors and hedge funds held shares of Cyclacel Pharmaceuticals shares: Sio Capital Management LLC ($491K), McIlrath & Eck LLC ($38K), Kestra Advisory Services LLC ($34K), and Raymond James Financial Services Advisors Inc. ($30K), Acadian Asset Management LLC ($29K).Learn more on CYCC's institutional investors. What percentage of Cyclacel Pharmaceuticals stock is owned by institutional investors? 23.58% of Cyclacel Pharmaceuticals stock is owned by institutional investors. Learn more on CYCC's institutional investor holdings. Which institutional investors have been buying Cyclacel Pharmaceuticals stock? The following institutional investors have purchased Cyclacel Pharmaceuticals stock in the last 24 months: Sio Capital Management LLC ($31.76K), McIlrath & Eck LLC ($26.34K), and Kestra Advisory Services LLC ($23K). How much institutional buying is happening at Cyclacel Pharmaceuticals? Institutional investors have bought a total of 81,099 shares in the last 24 months. This purchase volume represents approximately $1.60M in transactions. Which Cyclacel Pharmaceuticals major shareholders have been selling company stock? The following institutional investors have sold Cyclacel Pharmaceuticals stock in the last 24 months: Raymond James Financial Services Advisors Inc. ($10K), and Acadian Asset Management LLC ($9.94K). How much institutional selling is happening at Cyclacel Pharmaceuticals? Institutional investors have sold a total of 19,938 shares in the last 24 months. This volume of shares sold represents approximately $239.97K in transactions. Related Companies: Alzamend Neuro Institutional Ownership Petros Pharmaceuticals Institutional Ownership Ensysce Biosciences Institutional Ownership Exicure Institutional Ownership Soligenix Institutional Ownership Seelos Therapeutics Institutional Ownership ZyVersa Therapeutics Institutional Ownership Clever Leaves Institutional Ownership GT Biopharma Institutional Ownership GeoVax Labs Institutional Ownership This page (NASDAQ:CYCC) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Presidential candidate you should REALLY be worried aboutStansberry ResearchMost important medical advance in 100 yearsThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
